3546 results for «223»

Filter By

3546 results

Complex heart problems in cancer patients

19 May 2022 – From EuroPCR 2022

TAVI and thrombocytopenia, TAVI, CAD and hepatocarcinoma, or even severe aortic regurgitation and ovarian cancer with infective endocarditis: analyze the case of different cancer patients to be treated for cardiac pathologies in this session from EuroPCR 2022.

Complex heart problems in cancer patients

The cathlab of tomorrow... already here today

18 May 2022 – From EuroPCR 2022

Explore the 3 key pillars of innovation and discover how AI can improve patient safety and aid decision-making in the cathlab, what are the latest updates in robotic PCI and how it can be the transformative technology, and how technology can have a huge impact on...

The cathlab of tomorrow... already here today

First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent vs a durable fluoropolymer-based everolimus-eluting stent in patients with CAD: the ANGIOLITE trial

14 Jan 2020

The durable fluoroacrylate polymer-based sirolimus-eluting stent (Angiolite SES) has shown promising preclinical and clinical results regarding inflammatory vascular reaction and neointimal healing. J. Moreu, et al. aimed to compare performance between the Angiolite SES and an everolimus-eluting stent (EES) in patients with coronary artery disease.

Authors :

J. Moreu, R. Moreno-Gómez, A. Pérez de Prado, B. García del Blanco, R. Trillo, E. Pinar, E. Molina, J. Zueco, A. Merchán, J. Francisco Díaz-Fernández, I. Amat
EuroIntervention: the ANGIOLITE trial

Does metallic stent ablation by rotational atherectomy influence on the coronary microcirculation?

09 Jul 2019

An 80-year-old man underwent percutaneous coronary intervention with a bare-metal stent for severe stenosis at proximal left anterior descending coronary artery 13 years ago. In-stent restenosis was treated by a drug-eluting stent 1 year later...

Influence of stent ablation on the coronary microcirculation

5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

01 Apr 2025

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Yohei Ohno

Author

Yohei Ohno
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial
Didn’t find what you were looking for?